Reviving old antibiotics: Colistin SPCs

Colistin is arguably the first case in the antibacterial field where substantial “re-development” activities have been driven by academic and clinical investigators, rather than a sponsoring company. As a result of these activities, there is rapidly evolving new non-clinical and clinical knowledge on colistin. My recently published study investigated the variation and accuracy of information in the summary of product characteristics (SPCs) of intravenous colistin products approved in the European Union. This study highlights the challenges of integrating new rapidly evolving scientific knowledge into approved SPCs in Europe.

More information on regulatory issues of colistin:


One Response to Reviving old antibiotics: Colistin SPCs

  1. Juan Walterspiel MD FIDSA says:

    Those who picked this up voluntarily and at their own expense deserve a big price !

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s